Nature Communications (Dec 2021)

Discovery of an exosite on the SOCS2-SH2 domain that enhances SH2 binding to phosphorylated ligands

  • Edmond M. Linossi,
  • Kunlun Li,
  • Gianluca Veggiani,
  • Cyrus Tan,
  • Farhad Dehkhoda,
  • Colin Hockings,
  • Dale J. Calleja,
  • Narelle Keating,
  • Rebecca Feltham,
  • Andrew J. Brooks,
  • Shawn S. Li,
  • Sachdev S. Sidhu,
  • Jeffrey J. Babon,
  • Nadia J. Kershaw,
  • Sandra E. Nicholson

DOI
https://doi.org/10.1038/s41467-021-26983-5
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Suppressor of cytokine signaling (SOCS)2 protein is a key negative regulator of the growth hormone (GH) and Janus kinase (JAK)-Signal Transducers and Activators of Transcription (STAT) signaling cascade. The central SOCS2-Src homology 2 (SH2) domain is characteristic of the SOCS family proteins and is an important module that facilitates recognition of targets bearing phosphorylated tyrosine (pTyr) residues. Here we identify an exosite on the SOCS2-SH2 domain which, when bound to a non-phosphorylated peptide (F3), enhances SH2 affinity for canonical phosphorylated ligands. Solution of the SOCS2/F3 crystal structure reveals F3 as an α-helix which binds on the opposite side of the SH2 domain to the phosphopeptide binding site. F3:exosite binding appears to stabilise the SOCS2-SH2 domain, resulting in slower dissociation of phosphorylated ligands and consequently, enhances binding affinity. This biophysical enhancement of SH2:pTyr binding affinity translates to increase SOCS2 inhibition of GH signaling.